DOI: 10.6374 This Article Services Google Scholar PubMed TARGETING VASCULAR ENDOTHELIAL GROWTH FACTOR IN ADVANCED CARCINOID TUMOR: A RANDOM ASSIGNMENT PHASE II STUDY OF DEPOT OCTREOTIDE WITH BEVACIZUMAB AND PEGYLATED INTERFERON ALFA-2B JAMES C.ALEXANDRIA PHAN, PAULO M.HELEN X.CHUSILP CHARNSANGAVEJ, SAI-CHING J.KENNETH HESS, CHAAN NG, JAMES L.JAFFER A.The Departments of Gastrointestinal Medical Oncology, Diagnostic Imaging, General Internal Medicine, Ambulatory Treatment and the Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD Corresponding author: James C.MD, Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas M.Anderson Cancer, 1515 Hobe Blvd, Houston, TX 77030; e-mail: jyao{at}mdanderson.Purpose: Effective systemic therapy for advanced carcinoid is lacking.Of bevacizumab (BEV) and pegylated (PEG) interferon alfa-2b was evaluated among patients with metastatic or unresectable carcinoid tumors.Patients and Methods: Forty-four patients on stable doses of octreotide were randomly assigned to 18 weeks of treatment with bevacizumab or PEG interferon alfa-2b.Progression (PD) or at the end of 18 weeks (whichever occurred earlier), patients received bevacizumab plus PEG interferon until progression.Tomography (CT) scans were performed to measure effect on tumor blood flow.Results: In the bevacizumab arm, four patients (18%) achieved confirmed partial response (PR), 17 patients (77%) had stable disease (SD), and one patient (5%) had PD.PEG interferon arm, 15 patients (68%) had SD and six patients (27%) had PD.Survival (PFS) rates after 18 weeks of monotherapy were 95% in bevacizumab versus 68% on the PEG interferon arm.Overall median PFS for all 44 patients is 63 weeks.Paired baseline measurements on functional CT scans, we observed a 49% (_P_ < .28% (_P_ < .In tumor blood flow at day 2 and week 18 among patients treated with bevacizumab.Significant changes in tumor blood flow were observed following PEG interferon.Interferon alfa-2b treatment was associated with decrease in plasma basic fibroblast growth factor (bFGF; _P_ = .Increase in plasma interleukin-18 (IL-18; _P_ Supported in part by grants from National Cancer Institute (N01-CM-17003 and 22XSO94A), Schering Plough, and the American Society of Clinical Oncology.Trial was sponsored by Cancer Therapy Evaluation Program of NCI under the Clinical Research and Development Agreement (CRADA) with Genentech Inc.Presented in part at the American Society of Clinical Oncology Annual Meeting, Orlando, FL, May 13-17, 2005, and the 9th International Symposium on Anti-angiogenic Agents, February 1 to 3, 2007, San Diego, CA.Read more Inhaled insulin loses support
Get more Amiodarone increases mortality in post-mi patients with hf and/or lvsd
